Bulgaria's Etropal swings to 9-mo cons net profit

Etropal's total revenue grew to some 7.8 million levs in the reporting period from 4.7 million levs a year ago, the company said in an interim financial statement last week.

Operating expenses also increased, reaching 7.6 million levs from 5.4 million levs in the prior-year period. Expenses for materials more than doubled year-on-year to 3.5 million levs., but were offset by lower costs of goods sold and hired services.

Based in Etropole, western Bulgaria, Etropal is part of diversified group Synthetica [BUL:SYN] and makes medical consumables used for hemodialysis.

Shares in Etropal closed at 4.80 levs in the company's most recent trading session on the Bulgarian stock exchange on Monday.

(1 euro = 1.95583 levs)